Press Releases for TRMS

Press Releases
Trimeris Announces Extension of Arigene Tender Offer and Amendment of Merger Agreement
Trimeris Receives Request from Arigene for Extension of Tender Offer Period
Arigene Co., Ltd. Commences Tender Offer to Acquire All Outstanding Shares of Trimeris, Inc. Stock for $3.60 Per Share in Cash
Arigene Co., Ltd. To Acquire Trimeris, Inc.
Trimeris Reports Financial Results for the Second Quarter 2009
Trimeris Reports Second Quarter 2009 FUZEON® Sales Results
Trimeris Reports Financial Results for the First Quarter 2009
Trimeris Reports First Quarter 2009 FUZEON® Sales Results
Trimeris Discloses Tax Classification of 2008 Dividends
Trimeris Reports Financial Results for the Fourth Quarter and Year 2008
Trimeris Reports Fourth Quarter 2008 FUZEON® Sales Results
Zacks Bull & Bear of the Day Highlights: VistaPrint, Trimeris, Newmont Mining, Kinross Gold and Gilead Sciences
Trimeris Receives NASDAQ Audit Committee Deficiency Notification
Trimeris Announces Special Dividend
Zacks Analyst Blog Highlights: Coca-Cola Hellenic Bottling Co., Regeneron Pharmaceuticals, Inc., Denbury Resources Inc., Kinross Gold Corp. And Trimeris, Inc. - Nov 8 2008 12:31PM
Trimeris Reports Financial Results for the Third Quarter 2008
Trimeris to Release Third Quarter 2008 Financial Results on Thursday, November 6, 2008
Trimeris Reports Third Quarter 2008 FUZEON(R) Sales Results
Trimeris Reports Financial Results for the Second Quarter 2008 and Top-Line Results from Its Phase 1 Clinical Study of TRI-1144
Trimeris to Release Second Quarter 2008 Financial Results on Thursday, August 7, 2008
Trimeris Reports Second Quarter 2008 FUZEON(R) Sales Results
BeaconEquity.com Issues TraderNotes on Active Stocks: OPSY, WYNN, UCBH, ATML, TRMS, CENX, RSMI, FLWS
Trimeris Reports Financial Results for the First Quarter 2008 - Jun 3 2008 3:15AM
Trimeris to Release First Quarter 2008 Financial Results on Thursday, May 8, 2008 - Jun 3 2008 3:13AM
Trimeris Reports First Quarter 2008 FUZEON(R) Sales Results
Roche and Trimeris Announce Selection of Two Next Generation HIV Fusion Inhibitor Drug Candidates for Development
New Data Show Two-Thirds of Patients Achieve Undetectable Viral Load With FUZEON(R) and Investigational Protease Inhibitor
FDA Issues Approvable Letter in Response to Application for Use of FUZEON With Needle-Free Injection Device
Updated HIV/AIDS Treatment Guidelines Support Use of FUZEON Plus an Active Boosted Protease Inhibitor to Achieve New Treatment Goal
Notice to All Deutsche Bank Securities Inc. Customers Between 2000 and 2002: The Securities Arbitration Law Firm of Klayman & Toskes, P.A. Urges You to Explore Your Legal Options Regarding the Global Research Analyst Settlement Fund -- DB, GYI, ORCL, TKTX, TRMS
Data on New Options to Improve FUZEON Self-Injection Presented at International AIDS Conference
Roche and Trimeris Announce FDA Filing of FUZEON(R) sNDA for Administration with a Needle-Free Injection Device